Payment overview · 2025
General Payments
$126.67
5 reported records · 4 companies
Healthcare provider profile · identity verified
Ahmar Butt, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1619983871
Verified facts
What the public records show
CMS Open Payments records show Ahmar Butt, MD received $126.67 in general payments during 2025 across 5 reported records.
AstraZeneca Pharmaceuticals LP accounted for 43.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $55.21 | 43.6% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $32.49 | 25.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.93 | 16.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $18.04 | 14.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $126.67 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $55.21 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $32.49 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.93 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $18.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 20 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 425 | 168 |
| Amlodipine Besylate | Amlodipine Besylate | 326 | 107 |
| Mirtazapine | Mirtazapine | 202 | 47 |
| Metformin Hcl | Metformin Hcl | 172 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 166 | 69 |
| Gabapentin | Gabapentin | 153 | 62 |
| Famotidine | Famotidine | 149 | 55 |
| Nifedipine Er | Nifedipine | 145 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 124 | 50 |
| Losartan Potassium | Losartan Potassium | 117 | 55 |
| Furosemide | Furosemide | 115 | 47 |
| Levothyroxine Sodium | Levothyroxine Sodium | 112 | 39 |
| Montelukast Sodium | Montelukast Sodium | 104 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 101 | 22 |
| Xarelto | Rivaroxaban | 99 | 15 |
| Eliquis | Apixaban | 98 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 92 | 23 |
| Lisinopril | Lisinopril | 84 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 30 |
| Metformin Hcl Er | Metformin Hcl | 78 | 23 |
| Omeprazole | Omeprazole | 75 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 73 | 29 |
| Simvastatin | Simvastatin | 71 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 69 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 60 | 21 |
| Sertraline Hcl | Sertraline Hcl | 60 | 17 |
| Allopurinol | Allopurinol | 59 | 18 |
| Januvia | Sitagliptin Phosphate | 57 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 15 |
| Alprazolam | Alprazolam | 51 | suppressed |
| Celecoxib | Celecoxib | 51 | 21 |
| Ozempic | Semaglutide | 49 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 46 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 46 | 15 |
| Latanoprost | Latanoprost | 45 | 19 |
| Enulose | Lactulose | 41 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | suppressed |
| Carvedilol | Carvedilol | 39 | 20 |
| Entresto | Sacubitril/Valsartan | 39 | 18 |
| Labetalol Hcl | Labetalol Hcl | 39 | 14 |
| Cilostazol | Cilostazol | 38 | suppressed |
| Prednisone | Prednisone | 37 | 14 |
| Humalog Kwikpen U-100 | Insulin Lispro | 36 | suppressed |
| Levofloxacin | Levofloxacin | 36 | 30 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | 14 |
| Jardiance | Empagliflozin | 35 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 35 | 11 |
| Tramadol Hcl | Tramadol Hcl | 35 | 12 |
| Clotrimazole | Clotrimazole | 34 | 13 |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 16 |
| Novolog Flexpen | Insulin Aspart | 33 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | 13 |
| Divalproex Sodium | Divalproex Sodium | 30 | 11 |
| Silver Sulfadiazine | Silver Sulfadiazine | 30 | 12 |
| Spironolactone | Spironolactone | 30 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 29 | 28 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 29 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 16 |
| Finasteride | Finasteride | 28 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | 20 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 28 | 24 |
| Meloxicam | Meloxicam | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 26 | 26 |
| Naproxen | Naproxen | 26 | 22 |
| Brimonidine Tartrate | Brimonidine Tartrate | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Nyamyc | Nystatin | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 20 | 19 |
| Farxiga | Dapagliflozin Propanediol | 20 | 11 |
| Lactulose | Lactulose | 20 | suppressed |
| Minoxidil | Minoxidil | 20 | suppressed |
| Potassium Chloride | Potassium Chloride | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Methimazole | Methimazole | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | 11 |
| Baclofen | Baclofen | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 18 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Bumetanide | Bumetanide | 17 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | 12 |
| Sulfasalazine | Sulfasalazine | 16 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Hydroxyurea | Hydroxyurea | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | 13 |
| Nystatin | Nystatin | 15 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 15 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 14 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Cartia Xt | Diltiazem Hcl | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $126.67 · 5 records | AstraZeneca Pharmaceuticals LP | Cologuard Collection Kit, FARXIGA, REXULTI, Veozah | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error